SSGJ-705

SSGJ-705 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its targets are PD-1 and HER2. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-HER2 bispecifc antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials. The largest, NCT07022002, plans to enrol 340 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.